Meaningful outcome data are tumour-specific, stage-specific and reported from experienced centres. This page does not quote cure rates or complication percentages, because those numbers without full context can mislead.
Peer-reviewed journal articles, prospectively collected institutional series and randomised trials each have strengths and limits. Regulatory indications for devices differ by country and may not match off-label use discussed academically.
Your team will schedule PSA, imaging, biopsy or cross-sectional surveillance according to the organ treated and the risk category. Intervals are not identical for prostate, kidney, liver or pancreas.
You can ask for a second opinion on imaging, diagnosis and treatment options before you decide.
